-
Something wrong with this record ?
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
RS. Laureano, J. Sprooten, I. Vanmeerbeerk, DM. Borras, J. Govaerts, S. Naulaerts, ZN. Berneman, B. Beuselinck, KF. Bol, J. Borst, A. Coosemans, A. Datsi, J. Fučíková, L. Kinget, B. Neyns, G. Schreibelt, E. Smits, RV. Sorg, R. Spisek, K....
Language English Country United States
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2020
PubMed Central
from 2012
Europe PubMed Central
from 2012 to 1 year ago
Taylor & Francis Open Access
from 2020-01-01
- MeSH
- Antigens, Neoplasm MeSH
- Dendritic Cells MeSH
- Immunotherapy MeSH
- Humans MeSH
- Neoplasms * drug therapy MeSH
- Cancer Vaccines * therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to recent paradigm-shifts in immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed to tumor-associated or -specific antigens (TAAs or TSAs), in the presence of immunostimulatory molecules to induce DC maturation, followed by reinfusion into patients. Accordingly, DC vaccines can induce TAA/TSA-specific CD8+/CD4+ T cell responses. Yet, DC vaccination still shows suboptimal anti-tumor efficacy in the clinic. Extensive efforts are ongoing to improve the immunogenicity and efficacy of DC vaccines, often by employing combinatorial chemo-immunotherapy regimens. In this Trial Watch, we summarize the recent preclinical and clinical developments in this field and discuss the ongoing trends and future perspectives of DC-based immunotherapy for oncological indications.
Center for Cell Therapy and Regenerative Medicine Antwerp University Hospital Edegem Belgium
Department of General Medical Oncology UZ Leuven Leuven Belgium
Department of Haematology Antwerp University Hospital Edegem Belgium
Department of Immunology Charles University University Hospital Motol Prague Czech Republic
Department of Medical Oncology Radboud University Medical Center Nijmegen The Netherlands
Department of Medical Oncology UZ Brussel Brussels Belgium
Department of Neurosurgery UZ Leuven Leuven Belgium
Department of Tumour Immunology Radboud Institute for Molecular Life Sciences
Laboratory of Medical and Molecular Oncology Vrije Universiteit Brussel Brussels Belgium
Laboratory of Molecular and Cellular Therapy Vrije Universiteit Brussel Brussels Belgium
Radboud University Medical Center Nijmegen The Netherlands
Research Group Experimental Neurosurgery and Neuroanatomy KU Leuven Leuven Belgium
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22025277
- 003
- CZ-PrNML
- 005
- 20221031101316.0
- 007
- ta
- 008
- 221017s2022 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/2162402X.2022.2096363 $2 doi
- 035 __
- $a (PubMed)35800158
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Laureano, Raquel S $u Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium
- 245 10
- $a Trial watch: Dendritic cell (DC)-based immunotherapy for cancer / $c RS. Laureano, J. Sprooten, I. Vanmeerbeerk, DM. Borras, J. Govaerts, S. Naulaerts, ZN. Berneman, B. Beuselinck, KF. Bol, J. Borst, A. Coosemans, A. Datsi, J. Fučíková, L. Kinget, B. Neyns, G. Schreibelt, E. Smits, RV. Sorg, R. Spisek, K. Thielemans, S. Tuyaerts, S. De Vleeschouwer, IJM. de Vries, Y. Xiao, AD. Garg
- 520 9_
- $a Dendritic cell (DC)-based vaccination for cancer treatment has seen considerable development over recent decades. However, this field is currently in a state of flux toward niche-applications, owing to recent paradigm-shifts in immuno-oncology mobilized by T cell-targeting immunotherapies. DC vaccines are typically generated using autologous (patient-derived) DCs exposed to tumor-associated or -specific antigens (TAAs or TSAs), in the presence of immunostimulatory molecules to induce DC maturation, followed by reinfusion into patients. Accordingly, DC vaccines can induce TAA/TSA-specific CD8+/CD4+ T cell responses. Yet, DC vaccination still shows suboptimal anti-tumor efficacy in the clinic. Extensive efforts are ongoing to improve the immunogenicity and efficacy of DC vaccines, often by employing combinatorial chemo-immunotherapy regimens. In this Trial Watch, we summarize the recent preclinical and clinical developments in this field and discuss the ongoing trends and future perspectives of DC-based immunotherapy for oncological indications.
- 650 _2
- $a antigeny nádorové $7 D000951
- 650 12
- $a protinádorové vakcíny $x terapeutické užití $7 D019496
- 650 _2
- $a dendritické buňky $7 D003713
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoterapie $7 D007167
- 650 12
- $a nádory $x farmakoterapie $7 D009369
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Sprooten, Jenny $u Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium
- 700 1_
- $a Vanmeerbeerk, Isaure $u Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium
- 700 1_
- $a Borras, Daniel M $u Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium
- 700 1_
- $a Govaerts, Jannes $u Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium
- 700 1_
- $a Naulaerts, Stefan $u Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium $1 https://orcid.org/0000000218806374
- 700 1_
- $a Berneman, Zwi N $u Department of Haematology, Antwerp University Hospital, Edegem, Belgium $u Vaccine and Infectious Disease Institute, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium $u Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium
- 700 1_
- $a Beuselinck, Benoit $u Department of General Medical Oncology, UZ Leuven, Leuven, Belgium
- 700 1_
- $a Bol, Kalijn F $u Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences; Radboud University Medical Center, Nijmegen, The Netherlands $u Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
- 700 1_
- $a Borst, Jannie $u Department of Immunology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands
- 700 1_
- $a Coosemans, An $u Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, Ku Leuven, Leuven Cancer Institute, Leuven, Belgium
- 700 1_
- $a Datsi, Angeliki $u Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine University, Düsseldorf, Germany
- 700 1_
- $a Fučíková, Jitka $u Sotio Biotech, Prague, Czech Republic $u Department of Immunology, Charles University, University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Kinget, Lisa $u Department of General Medical Oncology, UZ Leuven, Leuven, Belgium
- 700 1_
- $a Neyns, Bart $u Department of Medical Oncology, UZ Brussel, Brussels, Belgium
- 700 1_
- $a Schreibelt, Gerty $u Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences; Radboud University Medical Center, Nijmegen, The Netherlands
- 700 1_
- $a Smits, Evelien $u Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium $u Center for Oncological Research, Integrated Personalized and Precision Oncology Network, University of Antwerp, Wilrijk, Belgium
- 700 1_
- $a Sorg, Rüdiger V $u Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine University, Düsseldorf, Germany
- 700 1_
- $a Spisek, Radek $u Sotio Biotech, Prague, Czech Republic $u Department of Immunology, Charles University, University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Thielemans, Kris $u Laboratory of Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium
- 700 1_
- $a Tuyaerts, Sandra $u Department of Medical Oncology, UZ Brussel, Brussels, Belgium $u Laboratory of Medical and Molecular Oncology, Vrije Universiteit Brussel, Brussels, Belgium
- 700 1_
- $a De Vleeschouwer, Steven $u Research Group Experimental Neurosurgery and Neuroanatomy, KU Leuven, Leuven, Belgium $u Department of Neurosurgery, UZ Leuven, Leuven, Belgium
- 700 1_
- $a de Vries, I Jolanda M $u Department of Tumour Immunology, Radboud Institute for Molecular Life Sciences; Radboud University Medical Center, Nijmegen, The Netherlands
- 700 1_
- $a Xiao, Yanling $u Department of Immunology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands
- 700 1_
- $a Garg, Abhishek D $u Laboratory of Cell Stress & Immunity, Department of Cellular & Molecular Medicine, KU Leuven, Leuven, Belgium $1 https://orcid.org/0000000299769922
- 773 0_
- $w MED00190079 $t Oncoimmunology $x 2162-402X $g Roč. 11, č. 1 (2022), s. 2096363
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35800158 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031101314 $b ABA008
- 999 __
- $a ok $b bmc $g 1854801 $s 1176567
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 11 $c 1 $d 2096363 $e 20220704 $i 2162-402X $m Oncoimmunology $n Oncoimmunology $x MED00190079
- LZP __
- $a Pubmed-20221017
